Biotech CEO discusses advancements in Alzheimer's and psychiatric disorder treatments, highlighting promising clinical results and future prospects |Stephan Jackman, CEO, Alzamend Neuro Inc. 00:10:00

Share On Facebook Share On Twitter

The CEO of a clinical stage biotech company specializing in Alzheimer's disease, bipolar disorder, major depressive disorder, and PTSD treatments discusses recent developments, including promising clinical trial results and future timelines for FDA submissions and commercialization.

Recent Videos